Thursday, November 5, 2026
BTC $75,877 ▼ 5.52%
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
LIVE
BTC$75,877down−5.52%ETH$2,252down−7.11%SOL$89.63down−6.43%XRP$1.24down−5.49%LINK$10.66down−7.50%ADA$0.182down−7.67%S&P 5007,414down−3.57%Nasdaq24,516down−4.74%Dow51,887down−2.75%RUT2,749down−3.76%TNX4.84%down−1.04%TYX5.25%down−0.51%FVX4.62%down−1.43%IRX4.00%down−0.62%VIX24.53up+47.68%GOLD$4,127.10up+1.33%SILVER$52.63up+0.66%OIL$90.44up+2.63%DXY101.46down−0.10%NVDA$184.27down−7.92%AAPL$344.64down−1.39%TSLA$341.36down−11.38%META$606.12down−3.79%MSFT$540.31down−2.79%AMZN$261.63down−1.65%GOOGL$285.71down−1.11%Fear & Greed50 — NeutralBTC$75,877down−5.52%ETH$2,252down−7.11%SOL$89.63down−6.43%XRP$1.24down−5.49%LINK$10.66down−7.50%ADA$0.182down−7.67%S&P 5007,414down−3.57%Nasdaq24,516down−4.74%Dow51,887down−2.75%RUT2,749down−3.76%TNX4.84%down−1.04%TYX5.25%down−0.51%FVX4.62%down−1.43%IRX4.00%down−0.62%VIX24.53up+47.68%GOLD$4,127.10up+1.33%SILVER$52.63up+0.66%OIL$90.44up+2.63%DXY101.46down−0.10%NVDA$184.27down−7.92%AAPL$344.64down−1.39%TSLA$341.36down−11.38%META$606.12down−3.79%MSFT$540.31down−2.79%AMZN$261.63down−1.65%GOOGL$285.71down−1.11%Fear & Greed50 — Neutral
Tag

vyvgart

1 article

Argenx's Vyvgart Franchise Offers 23% Upside; Four Studies Coming
U.S. Equities40d ago
Argenx's Vyvgart Franchise Offers 23% Upside; Four Studies Coming
The biotech reported 60% year-over-year revenue growth in Q2 2026 on gMG and CIDP therapies, with Wall Street's consensus target at $1,180.25.